This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kiernan, T. J. Articles by Simari, R. D. Search for Related Content PubMed PubMed Citation Articles by Kiernan, T. J. Articles by Simari, R. D. Related Collections Related Article

(Circulation Research. 2006;98:1341.)
© 2006 American Heart Association, Inc.

Editorials

Vasculoprotective Effects of Erythropoietin

New Developments and New Alternatives

Thomas J. Kiernan, Robert D. Simari

From the Cardiovascular Research Center, Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn.

Correspondence to Robert D. Simari, Cardiovascular Research Center, Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic College of Medicine, 200 1st Street SW, Rochester, MN 55905. E-mail simari.robert@mayo.edu

Key Words: cytokines • cell therapy • vascular injury

An extract of the first 250 words of the full text is provided, because this article has no abstract.

The body of evidence demonstrating the vasculoprotective effects of direct cell-based therapies to inhibit the acute response to vascular injury continues to grow. Delivery of autologous circulation-derived cells capable of assuming an endothelial phenotype to an injured arterial segment results in early reendothelialization and normalization of vascular function.^1–3 Current applications of this approach require cell isolation and modification in vitro, followed by direct delivery. However, novel approaches are being developed to avoid the inherent translational concerns of this strategy. Broadly, these new approaches include the mobilization and targeting of cell populations capable of augmenting reendothelialization of injured arteries while limiting neointimal formation. Multiple cytokines have been shown to mobilize cells capable of assuming an endothelial phenotype (broadly known as EPCs). These cytokines include VEGF, G-CSF, GM-CSF, and erythropoietin (Epo). The article by Urao et al⁴ in this issue of Circulation Research extends the observation that Epo can mobilize EPCs while demonstrating its ability to enhance reendothelialization and inhibit neointimal formation after vascular injury in an NO-dependent manner. Taken together, these findings extend our understanding of the role of Epo as a tissue protectant and apply it to the setting of acute vascular injury.

The article by Urao tested the hypothesis that systemic delivery of recombinant human Epo would inhibit neointimal formation in a mouse carotid artery wire injury model.⁴ Epo (1000 IU/kg of body weight) was administered for 3 days beginning at the time of arterial injury. Morphometric analysis of serial arterial sections performed at 14 days after injury showed . . . [Full Text of this Article]

Related Article:

Erythropoietin-Mobilized Endothelial Progenitors Enhance Reendothelialization via Akt-Endothelial Nitric Oxide Synthase Activation and Prevent Neointimal Hyperplasia

Norifumi Urao, Mitsuhiko Okigaki, Hiroyuki Yamada, Yasushi Aadachi, Kuniharu Matsuno, Akihiro Matsui, Shinsaku Matsunaga, Kento Tateishi, Tetsuya Nomura, Tomosaburo Takahashi, Tetsuya Tatsumi, and Hiroaki Matsubara
Circ. Res. 2006 98: 1405-1413. [Abstract] [Full Text] [PDF]